Olympus, EndoClot Plus Ink U.S. Distribution Deal

Olympus began a strategic distribution deal in the U.S. with EndoClot Plus Inc. (EPI).
 
EPI tech will complement Olympus’ GI endoscopy portfolio, providing new options for hemostasis and helping Olympus support EMR and ESD as well as endoscopic polyp, adenoma, early-stage cancer, and other gastrointestinal mucosal lesion removal.
 
“We are very excited to partner with a market-leading company in bringing our breakthrough technologies to market,” Stephen Heniges, president of EPI told the press. “With Olympus behind our solutions, we expect that market penetration will be swift and the real winners will be GI healthcare providers and their patients.”
 
Based in Santa Clara, Calif., EPI creates biomaterial therapeutic solutions for GI endoscopy. The firm also has operations in Suzhou, China.
 
“GI Hemostasis continues to be an area of focus for the GI EndoTherapy Business Unit,” said Mike Callaghan, global VP/GM EndoTherapy for Olympus Corp. of the Americas. “The EndoClot partnership reinforces our commitment to broaden our portfolio with clinically differentiated technologies that we can offer to our customers who treat patients with GI bleed disorders. I’m pleased that together with EndoClot, we will usher in a new standard of care in GI.”